AHA Coding Clinic® for ICD-9 - 2006 Issue 2; Ask the Editor
Methotrexate Induced Pneumonitis
A 56-year-old female was admitted with shortness of breath, low-grade fevers and headache. She underwent bronchoscopy with bronchoalveolar lavage. The patient had a history of rheumatoid arthritis and was receiving Methotrexate and Remicade therapy. The physician’s final diagnostic statement listed “Methotrexate induced pneumonitis.†Would code 486, Pneumonia, organism unspecified and the E-code for the causative agent be assigned, even though the medical literature describes this condition as an interstitial pneumonitis? How should this be coded? ...
Subscribe or sign in to view the full article.
Article Overview
This premium article discusses the coding of a methotrexate-associated pulmonary diagnosis in the context of rheumatoid arthritis treatment. It is aimed at coders and other revenue cycle professionals who need to understand how the condition is classified and what diagnosis coding guidance applies in this scenario. The article focuses on the diagnostic terminology, the coding question raised by the case, and the recommended classification used in the discussion.
Why This Topic Matters
Medication-related respiratory diagnoses can be coded differently from more general pneumonia terms, so correct classification affects claim accuracy and medical record reporting. This article helps readers understand how a specific clinical label is handled in coding guidance.
What You Will Learn
- How the article frames a methotrexate-associated pulmonary diagnosis
- What coding question is raised by the case scenario
- Which diagnosis classification is discussed in the article's guidance
- How the case relates to medication treatment and underlying autoimmune disease
Who Should Read This
- Medical coders
- Coding auditors
- Revenue cycle professionals
- Health information management staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com